Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer
Frontiers in Immunology · 24.11.2025 · 16
DOI: 10.3389/fimmu.2025.1663502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 24.11.2025. Verfasst von Yawen Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Proto-Oncogene Proteins p21(ras), Protein Kinase Inhibitors, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Ki-ras2 (KRAS) mutation is a common driver of lung cancer, and KRAS-mutated tumors are relatively resistant to radiotherapy. Previously, we demonstrated that mitogen-activated protein kinase (MEK) inhibitors (MEKi) enhanced treatment efficacy by increasing the anti-tumor immune response after radiotherapy in KRAS-mutant tumors. In this study, we explored the potential mechanism underlying the MEKi-mediated increase in anti-tumor immune response. Methods and result RNA sequencing revealed that the MEKi+radiotherapy combination significantly activated the chemokine signaling pathway. Blocking the C-X-C motif chemokine ligand 10 (CXCL10) receptor reduced T-cell infiltration in vivo . The MEKi+radiotherapy combination increased CXCL10 expression and activated the cyclic GMP–AMP synthase-stimulator of interferon genes (cGAS-STING) pathway in KRAS-mutant lung cell lines. Using a STING inhibitor and cGAS-knockout LLC cells, we showed that CXCL10 production was mediated by the cGAS-STING pathway via nuclear factor kappa B activation. This combination also increased DNA damage and apoptosis in KRAS-mutant lung cancer cell lines, triggering the cGAS-STING pathway. Western blot analysis revealed that MEKi reduced checkpoint kinase 2 phosphorylation after radiotherapy, hindering DNA repair and increasing DNA damage. Flow cytometry revealed that MEKi combined with radiotherapy boosted tumor-infiltrating CD4+ and CD8+ T cells in vivo , enhancing their cytotoxic and secretory functions. In an LLC-bearing mouse model, combining MEKi with varying radiotherapy doses and extending drug holidays revealed that low-dose radiotherapy with MEKi effectively controlled tumor growth.
Conclusion
Our findings suggest that MEKi activates the cGAS-STING-TANK-binding kinase 1-nuclear factor kappa B-CXCL10 axis post-radiotherapy in KRAS-mutant lung cancer, increasing T-cell infiltration and function, activating anti-tumor immunity, and inhibiting tumor growth. These results indicate the potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Research Center for Translational Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Department of Gastroenterology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Zitieren
APA
Zheng, Y., Su, C., Pan, J., Wang, Y., Zhao, M., Zhang, M., Yan, P., Liu, N., & Sun, M. (2025). Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1663502
Vancouver
Zheng Y, Su C, Pan J, Wang Y, Zhao M, Zhang M, et al. Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1663502
BibTeX
@article{Zheng2025,
author = {Zheng, Yawen and Su, Chen and Pan, Jiachao and Wang, Yufeng and Zhao, Mengmeng and Zhang, Mingyan and Yan, Peng and Liu, Ning and Sun, Meili},
title = {Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer},
journal = {Frontiers in Immunology},
year = {2025},
volume = {16},
doi = {10.3389/fimmu.2025.1663502}
}
EUVIMED